Abstract Number: 2240 • ACR Convergence 2024
Methotrexate Use Influenced the Effect of Inflammation on Cardiovascular Risk Differently in Anticitrullinated Protein Antibody Negative and Positive Patients with Rheumatoid Arthritis
Background/Purpose: Disease activity was linked to cardiovascular (CV) risk in rheumatoid arthritis (RA). Anticitrullinated protein antibody (ACPA) positivity associated with greater synovial inflammation, tumor necrosis…Abstract Number: 2166 • ACR Convergence 2023
Long-Term Effects of Abatacept on Arthritis and Atherosclerosis in Older vs Younger Patients with Rheumatoid Arthritis: 3-year Results of a Prospective, Multicenter, Observational Study
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of cardiovascular disease secondary to atherosclerosis. Although it has been reported that TNF inhibitor…Abstract Number: 0057 • ACR Convergence 2023
GM-CSF receptor/SYK/JNK/FOXO1/CD11c Signaling Enhances Cell Migration to Promote Atherosclerosis
Background/Purpose: Atherosclerosis involves both dyslipidemia and chronic inflammatory disease; however, lipid-lowering agents do not completely eliminate the risks of cardiovascular events. In addition, chronic systemic…Abstract Number: 0292 • ACR Convergence 2023
Comparison of Cardiovascular Risk of Myositis Patients and the General Population
Background/Purpose: Cardiovascular (CV) risk due to accelerated atherosclerosis and impaired metabolism can be increased in idiopathic inflammatory myopathies (IIM) on behalf of systemic inflammation, limited…Abstract Number: 0390 • ACR Convergence 2023
Statins Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis
Background/Purpose: Cholesterol efflux capacity (CEC) is the main antiatherogenic function of high-density lipoprotein (HDL). ATP-binding-cassette A1 (ABCA1) membrane transporter initiates cholesterol export from arterial macrophages…Abstract Number: 0552 • ACR Convergence 2023
The Impact of Antiphospholipid Antibodies on Future Atherosclerotic Cardiovascular Disease Risk in Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases (23·3 events per 1000 patient-years). Antiphospholipid antibodies (aPLs), including anticardiolipin…Abstract Number: 0568 • ACR Convergence 2023
Comparison of Plasma Protein Profiles and Endothelial Function in Patients with Pediatric-Onset Systemic Lupus Erythematosus and Healthy Controls
Background/Purpose: Patients with pediatric-onset systemic lupus erythematosus (pSLE) have elevated cardiovascular (CV) risk associated with accelerated atherosclerosis that begins in childhood. Endothelial dysfunction may be…Abstract Number: 0585 • ACR Convergence 2023
The Impact of Impaired Vagus Nerve Activity and Transcutaneous Vagus Nerve Stimulation (tVNS) on Arterial Stiffness in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease with an increased risk of atherosclerosis. The development of atherosclerosis in SLE cannot be…Abstract Number: 0654 • ACR Convergence 2023
Comparison of Cardiovascular Risk in Patients with Systemic Sclerosis and the General Population
Background/Purpose: Patients with systemic sclerosis (SSc) may be burdened by increased cardiovascular (CV) risk due to accelerated atherosclerosis (ATS) due to systemic inflammation, and vascular…Abstract Number: 0707 • ACR Convergence 2023
Prevalence and Distribution of Vascular Calcifications at CT Scan in Patients with Large Vessel Vasculitis and Patients with Lymphoma: A Matched Cross-sectional Study
Background/Purpose: Arterial wall calcifications are a hallmark of atherosclerosis and represent an important cardiovascular risk factor. Accelerated atherosclerosis and vascular calcifications have been reported in…Abstract Number: 0901 • ACR Convergence 2023
Scavenging of Isolevuglandins Attenuates Neutrophil Expansion and Aortic NETosis in Systemic Lupus Erythematosus
Background/Purpose: Atherosclerosis and vascular inflammation are a cause of morbidity and mortality in systemic lupus erythematosus (SLE). Vascular NETosis is a driver of atherosclerosis and…Abstract Number: 1283 • ACR Convergence 2023
Atherogenic Index of Plasma Identifies Patients with Rheumatoid Arthritis and Increased Carotid Intima-Media Thickness
Background/Purpose: The atherogenic index of plasma (AIP) is a novel marker to identify cardiovascular disease. Recently, AIP was reported to be related to long-term cardiovascular…Abstract Number: 1305 • ACR Convergence 2023
Variations in Macrophage Cholesterol Loading over Time Are Linked to Dynamic Changes in Coronary Atherosclerotic Plaque in Rheumatoid Arthritis
Background/Purpose: The ability of serum to deliver cholesterol to cells is known as cholesterol loading capacity (CLC) and associates with foam cell formation. In rheumatoid…Abstract Number: 2103 • ACR Convergence 2023
Inflammation and Immunomodulatory Therapies Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis
Background/Purpose: High-density lipoprotein (HDL) eliminates cholesterol from atherosclerotic lesions, a function known as cholesterol efflux capacity (CEC). ATP-binding-cassette A1 (ABCA1) membrane transporter initiates cholesterol transfer…Abstract Number: 1796 • ACR Convergence 2022
Peripheral Vascular Disease and Sequelae in Individuals with Gout, Diabetes, or Both Among US Veterans
Background/Purpose: Peripheral vascular disease (PVD) causes substantial morbidity and mortality. Patients with gout are known to have increased coronary artery disease risk but less is…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 17
- Next Page »